InvestorsHub Logo
Followers 18
Posts 643
Boards Moderated 0
Alias Born 05/19/2017

Re: Anonymous Fish post# 6156

Monday, 01/07/2019 9:09:06 AM

Monday, January 07, 2019 9:09:06 AM

Post# of 8508
Good question. I don’t have an answer.

If there is not a release of positive RSV-F results at the JPM Healthcare Conference, then it’ll be a buying opportunity from an intense FUD assault. NVAX’s VLP NanoFlu outcomes put them ahead of current vaccine makers by a remarkable margin (a definite threat to Sanofi’s FluZone HD) and signals a watershed moment in the field of disease prophylaxis.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NVAX News